Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin

International Journal of Cancer

Volumn 122, Issue 10, 2008, Pages 2368-2376

  Hadaschik, Boris A ^a   Ettinger, Susan ^a   Sowery, Richard D ^a,b   Zoubeidi, Amina ^a   Andersen, Raymond J ^b   Roberge, Michel ^b   Gleave, Martin E ^a,b,c  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Department of Urologic Sciences ^*  (Canada)

Author keywords

Antimitotic agent; Chemotherapy; Prostate cancer; Taxane resistance

Indexed keywords

ANDROGEN; DOCETAXEL; HEMIASTERLIN; NATURAL PRODUCT; PACLITAXEL; TALTOBULIN; TAXANE DERIVATIVE; TRIPEPTIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HTI-286; MESSENGER RNA; OLIGOPEPTIDE; RADIOSENSITIZING AGENT; TAXOID; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CANCER MORTALITY; CANCER PATIENT; CANCER RESISTANCE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG EXPOSURE; DRUG POTENCY; DRUG TARGETING; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROARRAY ANALYSIS; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; SPONGE (PORIFERA); TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; CELL CULTURE; CELL CYCLE; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DNA MICROARRAY; DRUG EFFECT; DRUG SCREENING; FLOW CYTOMETRY; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TAXOIDS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 42149107394     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23406     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 1998;160:1220-9.
3. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71:1098-109.
4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
5. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
6. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27.
7. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
8. Nieman JA, Coleman JE, Wallace DJ, Piers E, Lim LY, Roberge M, Andersen RJ. Synthesis and antimitotic/cytotoxic activity of hemiasterlin analogues. J Nat Prod 2003;66:183-99.
9. Zask A, Birnberg G, Cheung K, Kaplan J, Niu C, Norton E, Suayan R, Yamashita A, Cole D, Tang Z, Krishnamurthy G, Williamson R, et al. Synthesis and biological activity of analogues of the antimicrotubule agent N,β, β-trimethyl-L-phenylalanyl-N(1)-[(1S,2E)-3-carboxy-1-isopropylbu t-2-enyl]-N(1),3-dimethyl-L-valinamide (HTI-286). J Med Chem 2004;47:4774-86.
10. Ayral-Kaloustian S, Zask A. Taltobulin. Drugs Future 2005;30:254-60.
11. Nunes M, Kaplan J, Wooters J, Hari M, Minnick AA, Jr, May MK, Shi C, Musto S, Beyer C, Krishnamurthy G, Qiu Y, Loganzo F, et al. Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label α-tubulin. Biochemistry 2005;44:6844-57.
12. Ravi M, Zask A, Rush TS, III. Structure-based identification of the binding site for the hemiasterlin analogue HTI-286 on tubulin. Biochemistry 2005;44:15871-9.
13. Krishnamurthy G, Cheng W, Lo MC, Aulabaugh A, Razinkov V, Ding W, Loganzo F. Zask A, Ellestad G. Biophysical characterization of the interactions of HTI-286 with tubulin heterodimer and microtubules. Biochemistry 2003;42:13484-95.
14. Anderson HJ, Coleman JE, Andersen RJ, Roberge M. Cytotoxic peptides hemiasterlin, hemiasterlin A and hemiasterlin B induce mitotic arrest and abnormal spindle formation. Cancer Chemother Pharmacol 1997;39:223-6.
15. Loganzo F, Discafani CM, Annable T, Beyer C, Musto S, Hari M, Tan X, Hardy C, Hernandez R, Baxter M, Singanallore T, Khafizova G, et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res 2003;63:1838-45.
16. Loganzo F, Hari M, Annable T, Tan X, Morula DB, Musto S, Zask A, Kaplan J, Minnick AA, Jr, May MK, Ayral-Kaloustian S, Poruchynsky MS, et al. Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in α-tubulin. Mol Cancer Ther 2004;3:1319-27.
17. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54:2577-81.
18. Zhang X, Jackson JK, Burt HM. Development of amphiphilic diblock copolymers as micellar carriers of paclitaxel. Int J Pharm 1996;132:195-206.
19. Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K, Gleave ME. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 2002;8:3276-84.
20. Darzynkiewicz Z, Huang X, Okafuji M, King MA. Cytometric methods to detect apoptosis. Methods Cell Biol 2004;75:307-41.
21. Li Y, Li X, Hussain M, Sarkar FH. Regulation of microtubule, apoptosis, and cell cycle-related genes by taxotere in prostate cancer cells analyzed by microarray. Neoplasia 2004;6:158-67.
22. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;98:5116-21.
23. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996;6:986-94.
24. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991;51:3753-61.
25. Chen JG, Horwitz SB. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res 2002;62:1935-8.
26. Galletti E, Michela MM, Renzulli L, Maurizio B. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. Chem Med Chem 2007;2:920-42.
27. Dang LH, Bettegowda C, Agrawal N, Cheong I, Huso D, Frost P, Loganzo F, Greenberger L, Barkoczy J, Pettit GR, Smith AB, III, Gurulingappa H, et al. Targeting vascular and avascular compartments of tumors with C novyi-NT and anti-microtubule agents. Cancer Biol Ther 2004;3:326-37.
28. Vashist YK, Tiffon C, Stoupis C, Redaelli CA. Inhibition of hepatic tumor cell proliferation in vitro and tumor growth in vivo by taltobulin, a synthetic analogue of the tripeptide hemiasterlin. World J Gastroenterol 2006;12:6771-8.
29. Ratain MJ, Undevia S, Janisch L, Roman S, Mayer P, Buckwalter M, Foss D, Hamilton BL, Fischer J, Bukowski RM. Phase I and pharma-cological study of HTI-286, a novel antimicrotubule agent: correlation of neutropenia with time above a threshold serum concentration. Proc Am Soc Clin Oncol 2003;22: (Abstract 516).
30. Miyake H, Hara S, Arakawa S, Kamidono S, Hara I. Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model. Br J Cancer 2001;84:859-63.
31. Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, Wang Z, Gleave ME. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res 2005;11:4905-11.
32. Hadaschik BA, Sowery RD, Gleave ME. Novel targets and approaches in advanced prostate cancer. Curr Opin Urol 2007;17:182-7.
33. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-9.
34. Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT. EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 2007;67:547-56.
35. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 2004;23:5759-69.
36. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3:110-16.
37. Raymond MN, Bole-Feysot C, Banno Y, Tanfin Z, Robin P. Endothelin-1 inhibits apoptosis through a sphingosine kinase 1-dependent mechanism in uterine leiomyoma ELT3 cells. Endocrinology 2006;147:5873-82.
38. Titus B, Frierson HF, Jr, Conaway M, Ching K, Guise T, Chirgwin J, Hampton G, Theodorescu D. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 2005;65:7320-7.
39. Bao GC, Wang JG, Jong A. Increased p21 expression and complex formation with cyclin E/CDK2 in retinoid-induced pre-B lymphoma cell apoptosis. FEBS Lett 2006;580:3687-93.
40. Bartolini G, Orlandi M, Papi A, Ammar K, Guerra F, Ferreri AM, Rocchi P. A search for multidrug resistance modulators: the effects of retinoids in human colon carcinoma cells. In Vivo 2006;20:729-33.
41. Dvorak Z, Vrzal R, Ulrichova J, Macejova D, Ondkova S, Brtko J. Expression, protein stability and transcriptional activity of retinoic acid receptors are affected by microtubules interfering agents and alltrans-retinoic acid in primary rat hepatocytes. Mol Cell Endocrinol 2007;267:89-96.
42. Bergstralh DT, Ting JP. Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination. Cancer Treat Rev 2006;32:166-79.
43. Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave ME. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005;97:1287-96.
44. Groth-Pedersen L, Ostenfeld MS, Hoyer-Hansen M, Nylandsted J, Jaattela M. Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine. Cancer Res 2007;67:2217-25.